3rd Quarter - Report

INVARIANT LLC for ANTHEIA

Period 3rd Quarter 2023 Filed Oct 18, 2023 Signed by Laura Joshua

Official filing
Firm
INVARIANT LLC
Client
ANTHEIA
Income
$60,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Highlight Antheia's use of synthetic biology to produce active pharmaceutical ingredients and support initiatives that expand domestic production capabilities of API.

LobbyistCovered position, as disclosed
CHRISTOPHER GILLOTT —
JESSICA HATCHER New Leg. Dir, Rep. Jake Auchincloss (2021-2023); Sr. Legislative Asst, Rep. Pramila Jayapal (2020); Leg. Asst, Rep. Pramila Jayapal (2018-2020)
STEPHEN WEYLER —

Contacted: Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Executive Office of the President (EOP); SENATE

Defense DEF

Encourage support for the domestic manufacturing of active pharmaceutical ingredients.

LobbyistCovered position, as disclosed
CHRISTOPHER GILLOTT —
JESSICA HATCHER New Leg. Dir, Rep. Jake Auchincloss (2021-2023); Sr. Legislative Asst, Rep. Pramila Jayapal (2020); Leg. Asst, Rep. Pramila Jayapal (2018-2020)

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.